Jinwon Life Sciences Completes Enrollment of Participants for Phase 1 Clinical Trial of COVID-19 Vaccine

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 4th that it has completed the enrollment of a total of 45 participants for the Phase 1 clinical trial of the COVID-19 vaccine GLS-5310, currently underway at Korea University Guro Hospital.

The company stated, "The first dose has been completed for all participants in the Phase 1 clinical trial, and the second dose has begun," adding, "No serious adverse effects caused by the vaccine have been reported so far."

Park Younggeun, CEO of GeneOne Life Science, said, "With the cooperation of Korea University Guro Hospital, the enrollment of all participants in the Phase 1 clinical trial has been completed," and added, "Our company is also conducting challenge infection animal experiments to evaluate whether GLS-5310, developed early to prepare for virus mutations, effectively responds to variants such as the South African virus."